Moscow Endocrine Plant plans established commercial production of the drug Miorizon


The Ministry of Health of Russia registered the drug Miorizon, solution for intravenous and intramuscular injection, 100 mg/ml + 2.5 mg/ml” produced by Moscow Endocrine Plant, MEP press service reports.

The drug “Miorizon” is a central-acting muscle relaxant. The drug is used in adults for the symptomatic treatment of spasticity due to stroke, myofascial pain syndrome of moderate to severe degree (including muscle spasm in dorsopathies).

The company plans to release the first commercial series of the drug in the first quarter of 2021.